Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 3, Pages 62
Publisher
MDPI AG
Online
2018-03-01
DOI
10.3390/cancers10030062
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
- (2018) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC).
- (2017) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors
- (2017) Hsin-Yi Wang et al. Journal of Thoracic Oncology
- OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK + /ROS1 + Non-Small-Cell Lung Cancer
- (2017) B. Solomon et al. Journal of Thoracic Oncology
- ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2017) Byoung Chul Cho et al. Journal of Thoracic Oncology
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
- (2017) You-cai Zhu et al. OncoTargets and Therapy
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
- (2017) Mark M. Awad et al. Oncotarget
- Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene
- (2016) Hironori Kusano et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Transformation ofALKrearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
- (2016) N. Takegawa et al. ANNALS OF ONCOLOGY
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- (2016) Sen Zhang et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern
- (2016) Kana Sakamoto et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- (2016) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
- (2016) Tianhong Li et al. Journal of Hematology & Oncology
- Second- and third-generation ALK inhibitors for non-small cell lung cancer
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
- (2016) Wei-Sheng Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib
- (2016) Nishan Tchekmedyian et al. Journal of Thoracic Oncology
- Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
- (2016) Karen L. Reckamp et al. Journal of Thoracic Oncology
- A Case of ALK- Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
- (2016) Yoon Jin Cha et al. Journal of Thoracic Oncology
- Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
- (2016) Jessica J. Lin et al. Journal of Thoracic Oncology
- Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
- (2016) Shiro Fujita et al. Journal of Thoracic Oncology
- Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
- (2016) Justin F. Gainor et al. Journal of Thoracic Oncology
- Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- (2016) Scott N Gettinger et al. LANCET ONCOLOGY
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- (2016) Alice T Shaw et al. LANCET ONCOLOGY
- Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors
- (2016) Delphine Levacq et al. LUNG CANCER
- Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
- (2016) Masayoshi Miyawaki et al. MOLECULAR CANCER RESEARCH
- Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
- (2016) E. Ardini et al. MOLECULAR CANCER THERAPEUTICS
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
- (2016) Ryohei Katayama et al. EBioMedicine
- Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma
- (2015) H. Richly et al. BLOOD
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
- (2015) Frederick H. Wilson et al. CANCER CELL
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
- (2015) A. D. Amin et al. CANCER RESEARCH
- Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models
- (2015) Sen Zhang et al. CANCER RESEARCH
- Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib
- (2015) Shingo Miyamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non–small-cell Lung Cancer Exhibiting Resistance to Ceritinib
- (2015) Gouji Toyokawa et al. Journal of Thoracic Oncology
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
- (2015) Gorjan Hrustanovic et al. NATURE MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
- (2015) M Ceccon et al. ONCOGENE
- Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions
- (2015) Andrey V. Reshetnyak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adopting ALK and LTK
- (2015) Greg Lemke PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
- (2015) Helen Y. Zou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
- (2015) Phillip B. Murray et al. Science Signaling
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
- (2015) Phillip B. Murray et al. Science Signaling
- Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
- (2015) C. Voena et al. Cancer Immunology Research
- Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
- (2015) Diletta Fontana et al. Cancer Medicine
- The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
- (2015) Suraj Konnath George et al. Oncotarget
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.
- (2014) Rachel M. Squillace et al. CANCER RESEARCH
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Identification ofRANBP2-ALKfusion inALKpositive diffuse large B-cell lymphoma
- (2014) Seung Eun Lee et al. HEMATOLOGICAL ONCOLOGY
- Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC
- (2014) T. Tamura et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
- (2014) Carlo Gambacorti Passerini et al. JNCI-Journal of the National Cancer Institute
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- A Novel Fusion of TPR and ALK in Lung Adenocarcinoma
- (2014) Yoon-La Choi et al. Journal of Thoracic Oncology
- Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?
- (2014) Toyokawa Gouji et al. Journal of Thoracic Oncology
- A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
- (2014) F Abate et al. LEUKEMIA
- Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma
- (2014) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice
- (2014) M. Mori et al. MOLECULAR CANCER THERAPEUTICS
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
- (2014) Christine M Lovly et al. NATURE MEDICINE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo
- (2014) Christina Schönherr et al. Translational Oncology
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
- (2014) C. M. Lovly et al. Cancer Discovery
- STAT3 Pathway Is Activated in ALK-positive Large B-cell Lymphoma Carrying SQSTM1-ALK Rearrangement and Provides a Possible Therapeutic Target
- (2013) Emanuele S.G. d’Amore et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review
- (2013) Jian Li et al. Diagnostic Pathology
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- (2013) Thomas H. Marsilje et al. JOURNAL OF MEDICINAL CHEMISTRY
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
- (2013) Dara L. Aisner et al. MOLECULAR CANCER RESEARCH
- Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation
- (2013) Hyeong Ryul Kim et al. Molecular Oncology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish
- (2013) Sheng Yao et al. PLoS One
- ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages
- (2013) Adrian Mariño-Enríquez et al. Cancer Genetics
- A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK
- (2012) Hui-Yong Sun et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Identification of anaplastic lymphoma kinase fusions in renal cancer
- (2012) Emiko Sugawara et al. CANCER
- Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
- (2012) H. Ren et al. CANCER RESEARCH
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- (2012) Ramaswamy Govindan et al. CELL
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
- (2012) D. Chand et al. Disease Models & Mechanisms
- Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing
- (2012) Yeonjoo Jung et al. GENES CHROMOSOMES & CANCER
- ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients
- (2012) William R Sukov et al. MODERN PATHOLOGY
- Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
- (2012) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas
- (2012) Daniela Laimer et al. NATURE MEDICINE
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
- (2012) Yuki Togashi et al. PLoS One
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
- (2011) Kazutomo Kinoshita et al. BIOORGANIC & MEDICINAL CHEMISTRY
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066):
- (2011) Sen Zhang et al. CANCER RESEARCH
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1-ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification
- (2011) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
- (2011) M. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Crizotinib in Anaplastic Large-Cell Lymphoma
- (2011) Carlo Gambacorti-Passerini et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Evolutionary Conserved Role for Anaplastic Lymphoma Kinase in Behavioral Responses to Ethanol
- (2011) Amy W. Lasek et al. PLoS One
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
- (2011) S. C. Bresler et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning
- (2011) Jean Y. Gouzi et al. PLoS Genetics
- Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
- (2010) Roberto T. Bossi et al. BIOCHEMISTRY
- New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases
- (2010) F. Toffalini et al. BLOOD
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
- (2010) T. Sasaki et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
- (2010) S. De Brouwer et al. CLINICAL CANCER RESEARCH
- Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap
- (2010) J. Rohrbough et al. DEVELOPMENT
- ALK rearrangement in sickle cell trait-associated renal medullary carcinoma
- (2010) Adrián Mariño-Enríquez et al. GENES CHROMOSOMES & CANCER
- ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions
- (2010) K. Van Roosbroeck et al. HAEMATOLOGICA
- Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum
- (2010) Larisa V Debelenko et al. MODERN PATHOLOGY
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic lymphoma kinase: signalling in development and disease
- (2009) Ruth H. Palmer et al. BIOCHEMICAL JOURNAL
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- Anaplastic lymphoma kinase: an oncogene for tumor vaccination
- (2009) Cristina Mastini et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
- (2009) E. Lin et al. MOLECULAR CANCER RESEARCH
- C. elegans Anaplastic Lymphoma Kinase Ortholog SCD-2 Controls Dauer Formation by Modulating TGF-β Signaling
- (2008) David J. Reiner et al. CURRENT BIOLOGY
- An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features
- (2008) Sung-Ting Chen et al. HUMAN PATHOLOGY
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
- (2008) Roberto Chiarle et al. NATURE MEDICINE
- Activation of tyrosine kinases by mutation of the gatekeeper threonine
- (2008) Mohammad Azam et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started